Angeliq and Gastroesophageal reflux disease - a phase IV clinical study of FDA data

Summary:

Gastroesophageal reflux disease is reported only by a few people who take Angeliq.

The phase IV clinical study analyzes which people take Angeliq and have Gastroesophageal reflux disease. It is created by eHealthMe based on reports of 544 people who have side effects while taking Angeliq from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 03, 2023

544 people reported to have side effects when taking Angeliq.
Among them, 2 people (0.37%) have Gastroesophageal reflux disease.

What is Angeliq?

Angeliq has active ingredients of drospirenone; estradiol. It is often used in menopause. eHealthMe is studying from 585 Angeliq users for its effectiveness, alternative drugs and more.

What is Gastroesophageal reflux disease?

Gastroesophageal reflux disease (a condition in which stomach contents leak backward from the stomach into the oesophagus) is found to be associated with 3,684 drugs and 3,231 conditions by eHealthMe.

Number of Angeliq and Gastroesophageal reflux disease reports submitted per year:

Could Angeliq cause Gastroesophageal reflux disease?

Gender of people who have Gastroesophageal reflux disease when taking Angeliq *:

female: 100 %
male: 0.0 %

Age of people who have Gastroesophageal reflux disease when taking Angeliq *:

Common drugs people take besides Angeliq *:

Victoza: 1 person, 50.00%
Ozempic: 1 person, 50.00%
Benicar: 1 person, 50.00%
Amlodipine: 1 person, 50.00%

Common side effects people have besides Gastroesophageal reflux disease *:

Flatulence (flatus expelled through the anus): 2 people, 100.00%
Thirst: 1 person, 50.00%
Nausea And Vomiting: 1 person, 50.00%
Nausea (feeling of having an urge to vomit): 1 person, 50.00%
Hyperchlorhydria (gastric acid levels are higher in stomach): 1 person, 50.00%
Drug Ineffective: 1 person, 50.00%
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 1 person, 50.00%
Diarrhea: 1 person, 50.00%
Belching (release of gas from the digestive tract): 1 person, 50.00%
Abdominal Pain: 1 person, 50.00%

Common conditions people have *:

Insulin Resistance: 1 person, 50.00%
Hormone Level Abnormal: 1 person, 50.00%
High Blood Pressure: 1 person, 50.00%
Glucose Tolerance Impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis): 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Angeliq and have Gastroesophageal reflux disease?

Check whether Gastroesophageal reflux disease is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Gastroesophageal reflux disease and when was it recovered:

Gastroesophageal reflux disease in Angeliq

Expand to all the drugs that have ingredients of drospirenone; estradiol:

Gastroesophageal reflux disease and drugs with ingredients of drospirenone; estradiol (1 reports)

Alternative drugs to, pros and cons of Angeliq:

Angeliq (585 reports)

Gastroesophageal reflux disease treatments and more:

Gastroesophageal reflux disease (399,574 reports)

COVID vaccines that are related to Gastroesophageal reflux disease:

Common drugs associated with Gastroesophageal reflux disease:

All the drugs that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (3,684 drugs)

Common conditions associated with Gastroesophageal reflux disease:

High blood pressure: 8,283 reports
Osteoporosis: 6,304 reports
Pain: 4,963 reports

All the conditions that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (3,231 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on drospirenone; estradiol (the active ingredients of Angeliq) and Angeliq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.